Acute diarrhea medical therapy

Jump to navigation Jump to search

Acute Diarrhea Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute Diarrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Acute diarrhea medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute diarrhea medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute diarrhea medical therapy

CDC on Acute diarrhea medical therapy

Acute diarrhea medical therapy in the news

Blogs on Acute diarrhea medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Acute diarrhea medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • Fluid resuscitation (oral, if not IV)
  • Patients should be advised to do the following until symptoms subside:
  • For patients with lactose intolerance, a lactose-free diet is advised
  • For patients with malabsorption diseases, a gluten free diet is advised
  • Consultation with oncology, surgery and/or gastroenterology may be required for intestinal neoplasm
  • Control blood sugar (diabetic neuropathy)

Empirical Therapy

Empirical therapy is used as an initial treatment before diagnostic testing or after diagnostic testing has failed to confirm a diagnosis or when there is no specific treatment or when specific treatment fails to effect a cure.

  • Empirical trials of antimicrobial therapy like metronidazole for protozoal diarrhea or fluoroquinolone for enteric bacterial diarrhea if the prevalence of bacterial or protozoal infection is high in a specific community or situation.
  • Most cases of diarrhea, except for high-volume secretory states, respond to a sufficiently high dose of opium or morphine. Codeine, synthetic opioids diphenoxylate and loperamide are less potent. However loperamide is generally used because of its less abuse potential.
  • The somatostatin analogue octreotide has proven effectiveness in carcinoid tumors and other peptide-secreting tumors, dumping syndrome, and chemotherapy-induced diarrhea.
  • Intraluminal agents include adsorbants, such as activated charcoal, and binding resins like bismuth and stool modifiers, such as medicinal fiber.

Pharmacotherapy

Symptomatic Treatment

  • Symptomatic treatment for diarrhea involves the patient consuming adequate amounts of water to replace that loss, preferably mixed with electrolytes to provide essential salts and some amount of nutrients. For many people, further treatment is unnecessary.
  • The following types of diarrhea indicate medical supervision is required:
    • Diarrhea in infants;
    • Moderate or severe diarrhea in young children;
    • Diarrhea associated with blood;
    • Diarrhea that continues for more than two weeks;
    • Diarrhea that is associated with more general illness such as non-cramping abdominal pain, fever, weight loss, etc;
    • Diarrhea in travelers, since they are more likely to have exotic infections such as parasites;
    • Diarrhea in food handlers, because of the potential to infect others;
    • Diarrhea in institutions such as hospitals, child care centers, or geriatric and convalescent homes.

A severity score is used to aid diagnosis.[1]

Pathogen Specific

Immunocompetent

  • 1. Shigella species
  • Preferred regimen (1):
  • Preferred regimen (2):
  • 2. Non-typhi species of Salmonella
  • Preferred regimen: Not recommended routinely, but if severe or patient is younger than 6 monthes or older than 50 year old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) OR Fluoroquinolone, bid for 5 to 7 days; Ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses
  • 3. Campylobacter species
  • 4. Escherichia coli species
  • 4.1. Enterotoxigenic
  • 4.2. Enteropathogenic
  • 4.3. Enteroinvasive
  • 4.4. Enterohemorrhagic
  • Preferred regimen: Avoid antimotility drugs; role of antibiotics unclear, and administration should be avoided.
  • 5. Aeromonas/Plesiomonas
  • 6. Yersinia species
  • 7. Vibrio cholerae O1 or O139
  • Preferred regimen (1): Doxycycline 300-mg single dose
  • Preferred regimen (2): Tetracycline 500 mg qid for 3 days
  • Preferred regimen (3): TMP-SMZ 160 and 800 mg, respectively, bid for 3 days
  • Preferred regimen (4): single-dose Fluoroquinolone
  • 8. Toxigenic Clostridium difficile
  • Preferred regimen: Offending antibiotic should be withdrawn if possible; Metronidazole, 250 mg qid to 500 mg tid for 3 to 10 days
  • 1. Giardia
  • 2. Cryptosporidium species
  • Preferred regimen: If severe, consider Paromomycin, 500 mg tid for 7 days
  • 3. Isospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, bid for 7 to 10 days
  • 4. Cyclospora species
  • Preferred regimen: TMP/SMZ, 160 and 800 mg, respectively, bid for 7 days
  • 5. Microsporidium species
  • Preferred regimen: Not determined
  • 6. Entamoeba histolytica

Immunocompromised

  • 1. Shigella species:
  • Preferred regimen (1):
  • Preferred regimen (2):
  • 2. Non-typhi species of Salmonella
  • Preferred regimen: Not recommended routinely, but if severe or patient is younger than 6 monthes or older than 50 old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) OR Fluoroquinolone, bid for 14 days (or longer if relapsing); ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses
  • 3. Campylobacter species
  • Preferred regimen: Erythromycin, 500 mg bid for 5 days (may require prolonged treatment)
  • 4. Escherichia coli species
  • 4.1. Enterotoxigenic
  • 4.2. Enteropathogenic
  • 4.3. Enteroinvasive
  • 4.4. Enterohemorrhagic
  • Preferred regimen: Avoid antimotility drugs; role of antibiotics unclear, and administration should be avoided.
  • 5. Aeromonas/Plesiomonas
  • 6. Yersinia species
  • 7. Vibrio cholerae O1 or O139
  • 8. Toxigenic Clostridium difficile
  • Preferred regimen: Offending antibiotic should be withdrawn if possible; Metronidazole, 250 mg qid to 500 mg tid for 3 to 10 days
  • 1. Giardia
  • 2. Cryptosporidium species
  • Preferred regimen: Paromomycin, 500 mg tid for 14 to 28 days, then bid if needed; highly active antiretroviral therapy including a protease inhibitor is warranted for patients with AIDS
  • 3. Isospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, qid for 10 days, followed by TMP-SMZ thrice weekly, or weekly Sulfadoxine (500 mg) and Pyrimethamine (25 mg) indefinitely for patients with AIDS
  • 4. Cyclospora species
  • Preferred regimen: TMP-SMZ, 160 and 800 mg, respectively, qid for 10 days, followed by TMP-SMZ thrice weekly indefinitely
  • 5. Microsporidium species
  • Preferred regimen: Albendazole, 400 mg bid for 3 weeks; highly active antiretroviral therapy including a protease inhibitor is warranted for patients with AIDS
  • 6. Entamoeba histolytica

Contraindicated medications

Diarrhea is considered an absolute contraindication to the use of the following medications:

References

  1. Ruuska T, Vesikari T (1990). "Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes". Scand. J. Infect. Dis. 22 (3): 259–67. PMID 2371542.
  2. 2.0 2.1 2.2 2.3 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.

Template:WH Template:WS